VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average – Here’s What Happened

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.60 and traded as low as $0.55. VistaGen Therapeutics shares last traded at $0.5756, with a volume of 292,642 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, VistaGen Therapeutics has an average rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Trading Up 2.8%

The firm has a market capitalization of $22.81 million, a price-to-earnings ratio of -0.30 and a beta of 0.31. The company has a 50-day moving average of $0.60 and a 200-day moving average of $1.20.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new position in VistaGen Therapeutics during the 1st quarter worth $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of VistaGen Therapeutics in the third quarter valued at $39,000. Millennium Management LLC bought a new stake in VistaGen Therapeutics during the third quarter worth approximately $73,000. Bank of America Corp DE boosted its stake in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of VistaGen Therapeutics during the third quarter valued at $112,000. 78.39% of the stock is currently owned by institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.